5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

5 Must-Read Analyst Questions From 10x Genomics’s Q4 Earnings Call

Radek Strnad

Thu, February 19, 2026 at 2:38 PM GMT+9 4 min read

In this article:

TXG

+5.10%

10x Genomics’ fourth quarter results saw stable revenue performance despite a subdued research funding environment, with management crediting continued consumables growth and increased adoption of new products as key drivers. CEO Serge Saxonov pointed to strong momentum in single cell consumables, especially from the newly launched FLEX APEX assay, and double-digit consumables growth in the spatial segment. Management noted that late-quarter budget releases, particularly in EMEA, contributed to the quarter’s outcome. CFO Adam Taich highlighted disciplined cost control, which reduced operating expenses and supported a significant improvement in operating margin compared to last year.

Is now the time to buy TXG? Find out in our full research report (it’s free).

10x Genomics (TXG) Q4 CY2025 Highlights:

**Revenue:** $166 million vs analyst estimates of $159.2 million (flat year on year, 4.3% beat)

**Adjusted EPS:** $0.07 vs analyst estimates of -$0.04 (significant beat)

**Adjusted EBITDA:** $15.77 million (9.5% margin, 284% year-on-year growth)

**Operating Margin:** -11.8%, up from -30.2% in the same quarter last year

**Market Capitalization:** $2.5 billion

While we enjoy listening to the management’s commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From 10x Genomics’s Q4 Earnings Call

**Tycho Peterson (Jefferies)** asked about early 2026 ordering patterns and the timeline for clinical adoption. CEO Serge Saxonov described a steady environment with ongoing customer caution and reiterated that AI-driven and clinical projects are still in early but growing phases.

**Douglas Schenkel (Wolfe Research)** questioned the interplay between price and volume in single cell consumables. CFO Adam Taich explained that while reaction volumes are up, pricing headwinds exist as customers adopt lower-cost assays, resulting in flat premium consumables revenue at the midpoint of guidance.

**Daniel Arias (Stifel)** pressed for details on the push into clinical and translational markets. Saxonov described a two-pronged strategy: supporting customer-led clinical evidence generation and directly building out clinical capabilities, which are expected to be synergistic with research-focused business lines.

**Kyle Mikson (Canaccord)** asked about capital equipment headwinds and the biopharma opportunity. Saxonov pointed to ongoing constraints in CapEx, while Taich noted the company’s focus on consumables-driven growth and plans to expand biopharma’s revenue contribution over time.

**Michael Ryskin (Bank of America)** inquired about the Q1 revenue shift and late-quarter budget flush. Taich clarified that some orders arrived too late in Q4 to ship and rolled into Q1, resulting in a higher-than-usual first quarter revenue contribution.

 






Story Continues  

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) adoption rates and utilization trends for FLEX APEX and Xenium as indicators of consumables-driven growth, (2) the pace and impact of clinical collaborations and CLIA lab development on translational revenue, and (3) regional funding dynamics, especially in the U.S. and EMEA, for signs of a changing capital equipment environment. Continued innovation and customer uptake of new applications will also be critical milestones.

10x Genomics currently trades at $19.39, up from $17.51 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

Terms and Privacy Policy

Privacy Dashboard

More Info